ASH 2019 | Dual BCMA/GPRC5D targeting CAR-T for MM
Carlos Fernández De Larrea
• 7 Dec 2019
Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, outlines a study evaluating whether upfront simultaneous targeting of BCMA plus an additional antigen such as G protein-coupled receptor class C group 5 member D (GPRC5D) can mitigate BCMA escape-mediated relapse in multiple myeloma (MM). Dr de Larrea explains that dual targeting strategies were explored in vivo in order to identify an optimal approach. Results show that a single bicistronic vector encoding two 4-1BB-containing CARs avoids the practical challenges of parallel manufacturing and uniquely may provide superior anti-MM efficacy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
